Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes

Anticipated Profits From Biosimilar Candidates To Expand Future Development

12 May 2022

Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.

Gloved hand holding a vial and syringe — The two biosimilars should give Formycon's biosimilar business a significant boost • Source: Shutterstock

German biotech Formycon has completed the acquisition of two of Athos’ biosimilar candidates, as well as subsidiary operational development unit Bioeq GmbH, as part of a €650m ($686m) deal between the two firms.

Formycon expects to use the eventual profits from the transaction to fund further ventures in the biosimilar space, with chief financial officer Nicolas Combé remarking: “Within the framework of a long-term strategic partnership with our anchor investors, Formycon aims to become

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

16 May 2025

• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

16 May 2025

• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

15 May 2025